FULC insider trading plan sale: director unloads 15,000 shares

Rhea-AI Filing Summary

Fulcrum Therapeutics director reports sale of common stock under trading plan. A reporting person serving as a director of Fulcrum Therapeutics, Inc. (FULC) sold 15,000 shares of common stock on 11/19/2025 in an open market transaction at a weighted average price of $11.033 per share. After this sale, the individual beneficially owns 484,864 shares of Fulcrum common stock in direct form. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan that was adopted on August 1, 2025, which is intended to allow systematic selling according to preset instructions.

Insider Trade Summary

Net Seller: 15,000 shares ($165,495)

Net Sell 1 txn

Insider Gould Robert J

Role Director

Sold 15,000 shs ($165K)

Type	Security	Shares	Price	Value
Sale	Common Stock	15,000	$11.033	$165K

Holdings After Transaction: Common Stock — 484,864 shares (Direct)

Footnotes (1)

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.50 to $11.18, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gould Robert J

(Last) (First) (Middle)

C/O FULCRUM THERAPEUTICS, INC.

26 LANDSDOWNE STREET

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Fulcrum Therapeutics, Inc. [ FULC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/19/2025		S(1)		15,000	D	$11.033(2)	484,864	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.50 to $11.18, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

	/s/ Greg Tourangeau, as attorney-in-fact for Robert J. Gould	11/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Fulcrum Therapeutics (FULC) report in this Form 4?

The filing reports that a director of Fulcrum Therapeutics, Inc. (FULC) sold 15,000 shares of common stock on 11/19/2025 in an open market transaction.

At what price were the Fulcrum Therapeutics (FULC) shares sold in this insider trade?

The 15,000 shares of Fulcrum Therapeutics common stock were sold at a weighted average price of $11.033 per share, with individual trades executed between $10.50 and $11.18 per share.

How many Fulcrum Therapeutics (FULC) shares does the insider own after the reported sale?

Following the reported transaction, the director beneficially owns 484,864 shares of Fulcrum Therapeutics common stock held directly.

Was the Fulcrum Therapeutics (FULC) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2025.

Who is the reporting person in this Fulcrum Therapeutics (FULC) Form 4 and what is their role?

The reporting person is identified as a director of Fulcrum Therapeutics, Inc. The Form 4 is signed "/s/ Greg Tourangeau, as attorney-in-fact for Robert J. Gould", indicating it is filed on behalf of Robert J. Gould.

How is the sale price range for the Fulcrum Therapeutics (FULC) insider transaction described?

The filing explains that the reported $11.033 price is a weighted average. The 15,000 shares were sold in multiple transactions at prices ranging from $10.50 to $11.18, inclusive.